STRC Gene Therapy Research
TL;DR: Hub for all gene therapy research relevant to Misha’s STRC hearing loss (DFNB16). Core evidence base: Iranfar 2026 (first STRC mouse success), Gadenstaetter 2024 (bench-to-bedside overview), Verpy 2008 (OHC viability confirmation), Leclère 2024 (non-viral alternatives), Zhao 2025 (enhancer targeting), Jiang 2024 (multisite gene precedent). Together: the case that STRC gene therapy is viable, likely within 10 years, and Misha is an ideal candidate.
Research collection tracking the scientific basis for STRC gene therapy — the primary hope for restoring Misha’s hearing.
Status (as of 2026-03-19)
- Animal studies: ✅ Success — Iranfar et al. 2026 (dual-vector AAV, mouse, significant hearing restoration)
- Clinical trials: 🔄 Active — Regeneron AAV.104 program (preclinical), OTOF success paves the path
- Estimated human trials for STRC: 2026-2028 window
- Misha’s window: OHCs are alive and viable indefinitely → no time pressure from cell death (unlike GJB2)
Key Papers
Foundational
- Iranfar_2026_STRC_dual_AAV — first STRC hearing restoration in mice (Science Advances 2026)
- Verpy 2008 — STRC-null mice: OHCs survive indefinitely; DPOAE as therapy endpoint (Nature)
Delivery Systems
- Gadenstaetter_2024_inner_ear_gene_therapy_review — bench-to-bedside overview; STRC as high-priority dual-vector target (Mol Diagn Ther 2024)
- Leclere_2024_nonviral_vectors_hearing — LNP non-viral delivery: re-dosing possible, lower cost, emerging cochlear use (Hearing Research 2024)
Targeting & Specificity
- Zhao_2025_enhancers_hearing_loss_genes — OHC-specific enhancers (<500 bp) for STRC construct design (2025)
Precedent (Different Gene, Same Principle)
- Jiang_2024_hearing_restoration_DFNB111 — multisite gene replacement works; vestibular co-expression safe (AJHG 2024)
- duan_2018_micro_dystrophin_aav — oversized-gene AAV precedent from DMD micro-dystrophin
Structural Resources
- STRC Protein Visualization — UniProt Q7RTU9, 1809 aa; visualization project for strc.egor.lol; context for vector sizing (1809 aa = ~5.4 kb cDNA, dual-vector required)
Key Researchers (Contacted)
- Jeffrey Holt — Harvard Medical School; responded positively; lab working on STRC minigene
- Saaid Safieddine — Institut Pasteur Paris; dual-vector expertise
- Yilai Shu — Fudan University; China clinical trials
Critical Science
Why STRC is exceptional for gene therapy:
- OHCs remain alive indefinitely (Verpy 2008) — no time window closing
- Moderate loss (40-60 dB) — enough for meaningful recovery
- Non-syndromic — no systemic gene expression complications
- Mouse model validated (Iranfar 2026) — clean path to human trials
Main challenge: STRC gene (5,325 bp) exceeds single-AAV capacity → dual-vector required. Emerging alternative: Mini-STRC (N-terminal disordered region removed) may fit single AAV.
Connections
[about]Misha — this research exists for Misha[part-of]STRC Hearing Loss — core diagnosis note; situates gene therapy in full picture[see-also]STRC Mini-STRC Single-Vector Hypothesis — single-vector alternative hypothesis[see-also]STRC Dual-Vector vs Single-Vector Transduction — 56.5x advantage model[see-also]STRC AlphaFold3 Computational Experiments — structural analysis supporting therapy design[see-also]Prime Editing for STRC — prime editing as alternative to gene replacement[see-also]Alternative STRC Delivery Hypotheses — non-invasive delivery options[see-also]STRC Anti-AAV Immune Response Model — timing strategy for therapy access[see-also]Misha Hearing 10-Year Plan — the action plan this research informs[part-of]STRC Research Portal — public documentation at strc.egor.lol[part-of]Health & Wellness